IL-3 enhances both presentation of exogenous particulate antigen in association with class I major histocompatibility antigen and generation of primary tumor-specific cytolytic T lymphocytes

Journal of Immunology

Volumn 160, Issue 12, 1998, Pages 5773-5780

  Yeh, Kun Yun ^a   McAdam, Alexander J ^a,c   Pulaski, Beth A ^a,d   Shastri, Nilabh ^b   Frelinger, John G ^a   Lord, Edith M ^a  

^a UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF MARYLAND   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 3; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1;

ADENOCARCINOMA; ANIMAL CELL; ANTIGEN PRESENTATION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW CELL; CARCINOMA CELL; COLORIMETRY; CYTOLYSIS; EFFECTOR CELL; ENDOPLASMIC RETICULUM; GOLGI COMPLEX; INTERNALIZATION; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION;

ANIMALS; ANTIGEN-PRESENTING CELLS; BONE MARROW CELLS; CELLS, CULTURED; HISTOCOMPATIBILITY ANTIGENS CLASS I; INTERLEUKIN-3; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; OVALBUMIN; RECOMBINANT PROTEINS; T-LYMPHOCYTES, REGULATORY; TUMOR CELLS, CULTURED;

EID: 0032526908     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. York, I. A., and K. L. Rock. 1996. Antigen processing and presentation by the class I major histocompatibility complex. Annu. Rev. Immunol. 14:369.
2. Janeway, C. A., Jr., and K. Bottomly. 1994. Signals and signs for lymphocyte responses. Cell 76:275.
3. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA 90:4942.
4. Denkers, E. Y., R. T. Gazzinelli, S. Hieny, P. Caspar, and A. Sher. 1993. Bone marrow macrophages process exogenous Toxoplasma gondii polypeptides for recognition by parasite-specific cytolytic T lymphocytes. J. Immunol. 150:517.
5. Darji, A., T. Chakraborty, J. Wehland, and S. Weiss. 1995. Listeriolysin generates a route for the presentation of exogenous antigens by major histocompatibility complex class I. Eur. J. Immunol. 25:2967.
6. Pfeifer, J. D., M. J. Wick, R. L. Roberts, K. Findlay, S. J. Normark, and C. V. Harding. 1993. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:359.
7. Pulaski, B. A., A. J. McAdam, E. K. Hutter, S. Biggar, E. M. Lord, and J. G. Frelinger. 1993. Interleukin 3 enhances development of tumor-reactive cytotoxic cells by a CD4-dependent mechanism. Cancer Res. 53:2112.
8. Pulaski, B. A., K. Y. Yeh, N. Shastri, K. M. Maltby, D. P. Penney, E. M. Lord, and J. G. Frelinger, 1996. Interleukin 3 enhances cytotoxic T lymphocyte development and class I major histocompatibility complex re-presentation of exogenous antigen by tumor-infiltrat ing antigen-presenting cells. Proc. Natl Acad. Sci. USA 93:3669.
9. + T cells. Cell 71:1205.
10. Yuhas, J. M., N. H. Pazmino, J. O. Proctor, and R. E. Toya. 1974. A direct relationship between immune competence and the subcutaneous growth rate of a malignant murine lung tumor, Cancer Res. 34:722.
11. McAdam, A. J., B. A. Pulaski, E. Storozynsky, K. Y. Yeh, J. Z. Sickel, J. G. Frelinger, and E. M. Lord. 1995. Analysis of the effect of cytokines (interleukins 2, 3, 4, and 6, granulocyte-monocyte colony-stimulating factor, and interferon-gamma) on generation of primary cytotoxic T lymphocytes against a weakly immunogenic tumor. Cell. Immunol. 165:183.
12. Farrar, J. J., J. Fuller-Farrar, P. L. Simon, M. L. Hilfiker, B. M. Stadler, and W. L. Farrar. 1980. Thymoma production of T cell growth factor (interleukin 2). J. Immunol. 125:2555.
13. Kiessling, R., E. Klein, H. Pross, and H. Wigzell. 1975. "Natural" killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells: characteristics of the killer cell. Eur. J. Immunol. 5:117.
14. Sanderson, S., and N. Shastri. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Int. Immunol. 6:369.
15. McAdam, A. J., K. Y. Yeh, B. A. Pulaski, J. G. Frelinger, and E. M. Lord. 1993. Interleukin-3 inhibits the generation of nonspecific killers by interleukin-2. J. Immunother. 14:293.
16. Bahler, D. W., and E. M. Lord. 1985. Dimethyl sulfoxide induces expression of H-2 antigens on mouse lung carcinoma cells. J. Immunol. 134:2790.
17. Maryanski, J. L., J. Van Snick, J. C. Cerottini, and T. Boon. 1982. Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. III. Clonal analysis of the syngeneic cytolytic T lymphocyte response. Eur. J. Immunol. 12:401.
18. Yewdell, J. W., and J. R. Bennink. 1989. Brefeldin A specifically inhibits presentation of protein antigens to cytotoxic T lymphocytes. Science 244:1072.
19. Kovacsovics-Bankowski, M., and K. L. Rock. 1994. Presentation of exogenous antigens by macrophages: analysis of major histocompatibility complex class I and II presentation and regulation by cytokines. Eur. J. Immunol. 24:2421.
20. Ihle, J. N. 1992. Interleukin-3 and hematopoiesis. Chem. Immunol. 51:65.
21. Reis e Sousa, C., and R. N. Germain. 1995. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182:841.
22. Norbury, C. C., L. J. Hewlett, A. R. Prescott, N. Shastri, and C. Watts. 1995. Class I Mhc presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 3:783.
23. Keene, J. A., and J. Forman. 1982. Helper activity is required for the in vivo generation of cytotoxic T lymphocytes. J. Exp. Med. 155:768.
24. Goerdt, S., V. Kodelja, M. Schmuth, C. E. Orfanos, and C. Sorg. 1996. The mononuclear phagocyie-dedritic cell dichotomy: myths, facts and a revised concept. Clin. Exp. Immunol. 105:1.
25. Peters, J. H., R. Gieseler, B. Thiele, and F. Steinbach. 1996. Dendritic cells: from ontogenetic orphans to myelomonocytic descendants. Immunol. Today 17:273.
26. Debrick, J. E., P. A. Campbell, and U. D. Staerz. 1991. Macrophages as accessory cells for class I MHC-restricted immune responses. J. Immunol. 147:2846.
27. Kabel, P. J., M. de Haan-Meulman, H. A. Voorbij, M. Kleingeld, E. F. Knol, and H. A. Drexhage. 1989. Accessory cells with a morphology and marker pattern of dendritic cells can be obtained from elutriator-purified blood monocyte fractions: an enhancing effect of metrizamide in this differentiation. Immunobiology 179: 395.
28. Szabolcs, P., D. Avigan, S. Gezelter, D. H. Ciocon, M. A. Moore, R. M. Steinman, and J. W. Young. 1996. Dendritic cells and macrophages can mature independently from a human bone marrow-derived, post-colony-forming unit intermediate. Blood 87:4520.
29. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
30. Gordon, R. D., B. J. Mathieson, L. E. Samelson, E. A. Boyse, and E. Simpson. 1976. The effect of allogeneic presensitization on H-Y graft survival and in vitro cell-mediated responses to H-y antigen. J. Exp. Med. 144:810.
31. Gooding, L. R., and C. B. Edwards. 1980. H-2 antigen requirements in the in vitro induction of SV40-specific cytotoxic T lymphocytes. J. Immunol. 124:1258.
32. Harding. C. V. 1996. Class I MHC presentation of exogenous antigens. J. Clin. Immunol. 16:90.
33. + T cells in vitro. Eur. J. Immunol. 25:1274.
34. Srivastava, P. K., and H. Udono. 1994. Heat shock protein-peptide complexes in cancer immunotherapy. Curr. Opin. Immunol. 6:728.
35. Carbone, F. R., and M. J. Bevan. 1990. Class I-restricted processing and presentation of exogenous cell-associated antigen in vivo. J. Exp. Med. 171:377.
36. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243.
37. Stoppacciaro, A., G. Forni, and M. P. Colombo. 1994. Different tumours, transduced with different cytoline genes as G-CSF and IL-2, show inhibition of tumour take through neutrophil activation but differ in T cell functions. Folia Biol. 40:89.
38. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
39. Huang, A. Y., P. Golumbek, M. Ahmadzadeh, E. Jaffee, D. Pardoll, and H. Levitsky. 1994. Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science 264:961.